Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Cancer ; 24(1): 585, 2024 May 13.
Article in English | MEDLINE | ID: mdl-38741038

ABSTRACT

OBJECTIVE: The optimal timing for surgery following neoadjuvant immunochemotherapy for lung squamous cell carcinoma appears to be a topic of limited data. Many clinical studies lack stringent guidelines regarding this timing. The objective of this study is to explore the effect of the interval between neoadjuvant immunochemotherapy and surgery on survival outcomes in patients with lung squamous cell carcinoma. METHODS: This study conducted a retrospective analysis of patients with lung squamous cell carcinoma who underwent neoadjuvant immunochemotherapy between January 2019 and October 2022 at The First Affiliated Hospital, Zhejiang University School of Medicine. Patients were divided into two groups based on the treatment interval: ≤33 days and > 33 days. The primary observational endpoints of the study were Disease-Free Survival (DFS) and Overall Survival (OS). Secondary observational endpoints included Objective response rate (ORR), Major Pathological Response (MPR), and Pathological Complete Remission (pCR). RESULTS: Using the Kaplan-Meier methods, the ≤ 33d group demonstrated a superior DFS curve compared to the > 33d group (p = 0.0015). The median DFS for the two groups was 952 days and 590 days, respectively. There was no statistical difference in the OS curves between the groups (p = 0.66), and the median OS was not reached for either group. The treatment interval did not influence the pathologic response of the tumor or lymph nodes. CONCLUSIONS: The study observed that shorter treatment intervals were associated with improved DFS, without influencing OS, pathologic response, or surgical safety. Patients should avoid having a prolonged treatment interval between neoadjuvant immunochemotherapy and surgery.


Subject(s)
Carcinoma, Squamous Cell , Lung Neoplasms , Neoadjuvant Therapy , Humans , Male , Neoadjuvant Therapy/methods , Female , Lung Neoplasms/therapy , Lung Neoplasms/mortality , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Middle Aged , Retrospective Studies , Aged , Carcinoma, Squamous Cell/therapy , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Disease-Free Survival , Pneumonectomy , Time-to-Treatment , Adult , Treatment Outcome
2.
J Thorac Dis ; 15(11): 6238-6250, 2023 Nov 30.
Article in English | MEDLINE | ID: mdl-38090327

ABSTRACT

Background: Currently, the appropriate treatment of satellite lesions is still controversial. With this study, we aimed to construct a set of nomograms to determine the characteristics of satellite lesions in patients with multiple pulmonary ground glass nodules (MPGGNs) and propose a reference for the management of satellite lesions. Methods: We retrospectively analyzed patients with MPGGNs who had undergone multiple rounds of surgical resection of primary and satellite lesions, including pathologic examinations after surgical resection. Results: A total of 125 lesions from 105 patients were included in the analysis; 85 lesions were advanced and 40 lesions were not advanced. Among them, 55 invasive pulmonary adenocarcinomas (IPA) and 70 noninvasive pulmonary adenocarcinomas were identified. After the final regression analysis, the patients' age, satellite lesion location, consolidation tumor ratio (CTR), lesion border clarity, and lesion diameter were used to predict satellite lesion progression. Patients' gender, satellite lesion location, lesion diameter, and computed tomography (CT) attenuation values were used to predict the invasiveness of the satellite lesion. The constructed nomograms showed strong discrimination with concordance indices (C indices) of 0.816 and 0.823, respectively. Conclusions: We developed a set of nomograms that can predict the risk of advanced or invasive satellite lesions in patients with MPGGNs. The area under the receiver operating characteristic (ROC) curve (AUC), the C-index, and the calibration curve suggest that the nomogram may be useful in the clinical setting. This model has the potential to help clinicians make treatment recommendations for the remaining lesions while treating the primary lesion in patients with MPGGNs.

3.
J Cardiothorac Surg ; 18(1): 300, 2023 Oct 27.
Article in English | MEDLINE | ID: mdl-37891645

ABSTRACT

INTRODUCTION: The efficacy of erector spinae plane block versus paravertebral block for thoracoscopic surgery remains controversial. We conduct a systematic review and meta-analysis to explore the impact of erector spinae plane block versus paravertebral block on thoracoscopic surgery. METHODS: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2022 for randomized controlled trials (RCTs) assessing the effect of erector spinae plane block versus paravertebral block on thoracoscopic surgery. This meta-analysis is performed using the random-effect model. RESULTS: Seven RCTs are included in the meta-analysis. Overall, compared with erector spinae plane block for thoracoscopic surgery, paravertebral block results in significantly reduced pain scores at 12 h (SMD = 1.12; 95% CI 0.42 to 1.81; P = 0.002) and postoperative anesthesia consumption (SMD = 1.27; 95% CI 0.30 to 2.23; P = 0.01), but these two groups have similar pain scores at 1-2 h (SMD = 1.01; 95% CI - 0.13 to 2.15; P 0.08) and 4-6 h (SMD = 0.33; 95% CI - 0.16 to 0.81; P = 0.19), as well as incidence of nausea and vomiting (OR 0.93; 95% CI 0.38 to 2.29; P = 0.88). CONCLUSIONS: Paravertebral block may be better for the pain relief after thoracoscopic surgery than erector spinae plane block.


Subject(s)
Nerve Block , Humans , Randomized Controlled Trials as Topic , Pain Management , Thoracoscopy , Pain , Pain, Postoperative/prevention & control
4.
Front Bioeng Biotechnol ; 10: 892613, 2022.
Article in English | MEDLINE | ID: mdl-36091439

ABSTRACT

Recent studies have confirmed the existence of microbiota in the lungs. The relationship between lung ground-glass opacity (GGO) and microbiota in the lung microenvironment is not clear. In this study, we investigated the microbial composition and diversity in bronchoalveolar lavage fluid (BALF) of diseased lung segments and paired contralateral healthy lung segments from 11 GGO patients. Furthermore, lung GGO and paired normal tissues of 26 GGO patients were explored whether there are microbial characteristics related to GGO. Compared with the control group, the community richness of GGO tissue and BALF of GGO lung segment (α-diversity) and overall microbiome difference (ß-diversity) had no significant difference. The microbiome composition of BALF of GGO segments is distinct from that of paired healthy lung segments [genus (Rothia), order (Lachnospiraceae), family (Lachnospiraceae), genus (Lachnospiraceae_NK4A136_group, Faecalibacterium), and species (Faecalibacterium prausnitzii, Bacteroides uniforms)]. GGO tissue and adjacent lung tissue had more significant differences at the levels of class, order, family, genus, and species level, and most of them are enriched in normal lung tissue. The area under the curve (AUC) using 10 genera-based biomarkers to predict GGO was 91.05% (95% CI: 81.93-100%). In conclusion, this study demonstrates there are significant differences in the lower respiratory tract and lung microbiome between GGO and the non-malignant control group through the BALF and lung tissues. Furthermore, some potential bacterial biomarkers showed good performance to predict GGO.

5.
Am J Transl Res ; 14(2): 728-739, 2022.
Article in English | MEDLINE | ID: mdl-35273681

ABSTRACT

OBJECTIVES: To study the role of miR-133a expression in the invasion, proliferation, migration, and apoptosis of lung cancer cells and its mechanism. METHODS: miR-133a expression levels in human normal lung epithelial cells (BEAS-2B), H441 cell lines and NSCLC tissues were detected by qPCR. The influence of miR-133a mimics on the migration, proliferation and invasion of H441 cells was examined by CCK-8 assay, transwell migration assay, and invasion assay, respectively. Expression of MMP-9 and LASP1 in H441 cellstreated by miR-133a mimics was determined by western blot. Pearson's test was conducted to study the association of miR-133a expression with clinical characteristics of NSCLC patients. The targeted regulation of miR-133a on LASP1 gene expression was detected by the luciferase reporter gene assay. RESULTS: miR-133a expression was decreased in H441 cells in contrast to that in BEAS-2B cells (P<0.05). Compared with para-carcinoma tissues, miR-133a levels were markedly down-regulated in NSCLC tissues. miR-133a overexpression inhibited the invasion, proliferation, and migration ability of H441 cells and promoted cell apoptosis (all P<0.05). MMP-9 expression levels were also reduced in the miR-133a mimic group. Moreover, miR-133a expression levels were correlated with tumor size and TNM stage. miR-133a overexpression decreased the expression of LASP1, which is the targeted gene of miR-133a. CONCLUSIONS: miR-133a overexpression can reduce the invasion, proliferation, migration, and matrix metalloproteinase expression of NSCLC cells and promote cell apoptosis. This may be correlated to targeted down-regulation of LASP1 expression.

SELECTION OF CITATIONS
SEARCH DETAIL
...